# Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

> **NCT00004198** · PHASE2 · COMPLETED · sponsor: **University of Nebraska**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** keyhole limpet hemocyanin
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** tumor cell-based vaccine therapy

## Key facts

- **NCT ID:** NCT00004198
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06-25
- **Primary completion:** 2002-01-01
- **Final completion:** 2003-11-20
- **Target enrollment:** — (—)
- **Last updated:** 2023-12-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004198, "Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00004198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*